SuperGen Presentations at AACR-NCI-EORTC
DUBLIN, Calif.--(BUSINESS WIRE)--Nov 9, 2009 - SuperGen, Inc. (Nasdaq:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of seven abstracts for poster presentations on November 16, 17 and 18, 2009 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, MA.
SuperGen's presentations will review clinical and non-clinical advances in the following compounds: MP-470, SGI-1776, SGI-110, SGI-1252, as well as two presentations on the Etk program. The posters will be made available for viewing on the company's website www.supergen.com following the respective presentations.
|
MP-470: The tyrosine kinase inhibitor MP470 inhibits
RAD51-mediated homologous recombination and increases tumor cell
radio- and chemosensitivity
|
| Abstract A122, Monday Nov 16, 12:30 – 2:30 pm EST |
|
SGI-110: In vivo activity of SGI-110, a novel
hypomethylating agent for treatment in hematology and solid
malignancies
|
| Abstract A190, Monday Nov 16, 12:30 – 2:30 pm EST |
|
MP-470: A self-emulsifying lipid suspension formulation
enhances oral bioavailability of MP-470 in a randomized two-way
crossover study in healthy male subjects
|
| Abstract B209, Tuesday Nov 17, 12:30 – 2:30 pm EST |
|
SGI-1776: The novel PIM kinase inhibitor SGI-1776
significantly enhances the preclinical activity of sunitinib in
renal cell carcinoma
|
| Abstract
B272, Tuesday Nov 17, 12:30 – 2:30 pm EST
|
|
ETK/BMX: Mechanistic, functional and in vivo efficacy of
inhibiting ETK/BMX in cancer models
|
| Abstract B263, Tuesday Nov 17, 12:30 – 2:30 pm EST |
|
SGI-1252: In vivo activity of SGI-1252, a potent,
small-molecule dual inhibitor of JAK2 and ALK2
|
| Abstract C206, Wednesday Nov 18, 12:30 – 2:30 pm EST |
| ETK:
Development of potent, small-molecule inhibitors of ETK
|
| Abstract C199 Wednesday Nov 18, 12:30 – 2:30 pm EST |
SuperGen is a pharmaceutical company dedicated to the discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. For more information about SuperGen, please visit http://www.supergen.com.
Contact: SuperGen, Inc.
Timothy L. Enns, 925-560-2810
Senior Vice President
Corporate Communications & Business Development
tenns@supergen.com
Susanna Chau, 925-560-2845
Manager
Investor Relations
schau@supergen.com
Posted: November 2009
